Diagnosis, severity, and recovery of attacks in the N-MOmentum study of inebilizumab in Neuromyelitis optica spectrum disorder

被引：0

作者：

Weinshenker, B. ^{[1
]}

Wingerchuk, D. ^{[2
]}

Green, A. ^{[3
]}

Bennett, J. ^{[4
]}

Kim, H. J. ^{[5
]}

Pittock, S. ^{[1
]}

Fujihara, K. ^{[6
]}

Paul, F. ^{[7
,8
,9
,10
]}

Cutter, G. ^{[11
]}

Marignier, R. ^{[12
]}

Aktas, O. ^{[13
]}

Hartung, H. -P. ^{[13
]}

Drappa, J. ^{[14
]}

Barron, G. ^{[15
]}

Madani, S. ^{[14
]}

Ratchford, J. ^{[14
]}

Shi, D. ^{[14
]}

Cimbora, D. ^{[14
]}

Katz, E. ^{[14
]}

Cree, B. ^{[3
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Mayo Clin, Scottsdale, AZ USA

[3] Univ Calif San Francisco, Weill Inst Neurosci, Neurol, San Francisco, CA 94143 USA

[4] Univ Colorado, Sch Med, Neurol & Ophthalmol, Denver, CO USA

[5] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea

[6] Fukushima Med Univ, Sch Med, Fukushima, Japan

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Free Univ Berlin, Berlin, Germany

[9] Humboldt Univ, Berlin, Germany

[10] Berlin Inst Hlth, Berlin, Germany

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] Hosp Civils Lyon, Lyon, France

[13] Heinrich Heine Univ, Dusseldorf, Germany

[14] Viela Bio, Gaithersburg, MD USA

[15] Astrazeneca, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P358

引用

页码：137 / 138

页数：2

共 50 条

[1] Diagnosis, Severity and Recovery of Attacks in the N-MOmentum Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
Paul, F.
Weinshenker, B. G.
Wingerchuk, D.
Green, A.
Bennett, J. L.
Kim, H. J.
Pittock, S.
Fujihara, K.
Cutter, G.
Marignier, R.
Aktas, O.
Hartung, H-P
Drappa, J.
Barron, G.
Madani, S.
Ratchford, J. N.
She, D.
Cimbora, D.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP80 - NP82
[2] Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
Marignier, Romain
Bennett, Jeffrey L.
Kim, Ho Jin
Weinshenker, Brian G.
Pittock, Sean J.
Wingerchuk, Dean
Fujihara, Kazuko
Paul, Friedemann
Cutter, Gary R.
Green, Ari J.
Aktas, Orhan
Hartung, Hans-Peter
Lublin, Fred D.
Williams, Ian M.
Drappa, Jorn
She, Dewei
Cimbora, Daniel
Rees, William
Smith, Michael
Ratchford, John N.
Katz, Eliezer
Cree, Bruce A. C.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):
[3] Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study
Fujihara, Kazuo
Kim, Ho Jin
Saida, Takahiko
Misu, Tatsuro
Nagano, Yoshito
Totsuka, Naoko
Iizuka, Masato
Kido, Shinsuke
Terata, Ryuuji
Okumura, Kyoko
Hirota, Shinya
Cree, Bruce A. C.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
[4] Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study
Flanagan, Eoin P.
Levy, Michael
Katz, Eliezer
Cimbora, Daniel
Drappa, Jorn
Mealy, Maureen A.
She, Dewei
Cree, Bruce A. C.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
[5] Long term safety outcomes with inebilizumab treatment in neuromyelitis optica spectrum disorder: the N-MOmentum trial
Cree, B.
Bennett, J.
Weinshenker, B.
Wingerchuk, D.
Paul, F.
Kim, H.
Pittock, S.
Fujihara, K.
Cutter, G.
Marignier, R.
Aktas, O.
Hartung, H.
Green, A.
Drappa, J.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J.
Katz, E.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 176 - 176
[6] Long term efficacy outcomes with inebilizumab treatment in neuromyelitis optica spectrum disorder: the N-MOmentum trial
Cree, B.
Bennett, J.
Weinshenker, B.
Wingerchuk, D.
Paul, F.
Kim, H.
Pittock, S.
Fujihara, K.
Cutter, G.
Marignier, R.
Aktas, O.
Hartung, H.
Green, A.
Drappa, J.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J.
Katz, E.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 177 - 177
[7] Inebilizumab Reduces the Risk of Disability Progression in Neuromyelitis Optica Spectrum Disorder: Outcomes From the N-MOmentum Trial
Fujihara, K.
Marignier, R.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S. J.
Wingerchuk, D.
Paul, F.
Cutter, G.
Green, A.
Aktas, O.
Hartung, H-P
Lublin, F. D.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP82 - NP83
[8] Aqp4-igg seronegative patient outcomes in the n-momentum trial of inebilizumab in neuromyelitis optica spectrum disorder
Pittock, S.
Paul, F.
Marignier, R.
Kim, H. J.
Bennett, J.
Weinshenker, B.
Wingerchuk, D.
Green, A.
Fujihara, K.
Cutter, G.
Aktas, O.
Hartung, H. P.
Drappa, J.
Ratchford, J.
She, D.
Cimbora, D.
Katz, E.
Cree, B.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 208 - 209
[9] AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
Marignier, Romain
Pittock, Sean J.
Paul, Friedemann
Kim, Ho Jin
Bennett, Jeffrey L.
Weinshenker, Brian G.
Wingerchuk, Dean M.
Green, Ari J.
Fujihara, Kazuo
Cutter, Gary
Aktas, Orhan
Hartung, Hans-Peter
Drappa, Jorn
Ratchford, John N.
She, Dewei
Smith, Michael
Rees, William
Cimbora, Daniel
Katz, Eliezer
Cree, Bruce A. C.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
[10] Long-term Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder in the Randomized, Double-blind N-MOmentum Study and Extension
Cree, B. A. C.
Bennett, J. L.
Kim, H. J.
Weinshenker, B.
Pittock, S.
Wingerchuk, D.
Fujihara, K.
Paul, F.
Cutter, G.
Marignier, R.
Green, A.
Aktas, O.
Hartung, H-P.
Lublin, F.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
She, D.
Cimbora, D.
Rees, W.
Ratchford, J. N.
Katz, E.
NEUROLOGY, 2020, 94 (15)

← 1 2 3 4 5 →